Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Agilent Technologies Launch SurePrint G3 Microarray
April 20, 2009
- Merck Serono: Gonalef Subcutaneous Injection Pen
April 20, 2009
- Eisai Licenses Out Gliadel Wafer to Nobelpharma
April 20, 2009
- BUSINESS NEWS IN BRIEF
April 20, 2009
- Actavis ASKA Aims at Sales of ¥10 Bil. by 2015
April 13, 2009
- JKMA Publishes English Terminology for Kampo Medicines
April 13, 2009
- Co-DIO, Ecard Jump to 1st and 2nd Place on GP Market: Rep Track Survey
April 13, 2009
- 22 Companies to Apply for NHI Price Listing for Generics of Cravit
April 13, 2009
- Council to Focus on Differences in Prices of Medical Devices in Japan and Abroad
April 13, 2009
- Pharmacists Hold Key to Promotion of the Use of Generics: Mr Isobe
April 13, 2009
- MEDICAL DEVICE NEWS IN BRIEF
April 13, 2009
- Hansha's Sales Forces May Help Generics Makers Provide Information
April 13, 2009
- JCS (Japanese Circulation Society) 2009
April 13, 2009
- Mylan Seiyaku Kicks Off Cancer-Specialized Team
April 13, 2009
- Lucentis to Become the Mainstay for AMD in Japan as Well
April 13, 2009
- Society of Applied Therapeutics to Be Inaugurated
April 13, 2009
- Optimal Antiviral Therapy Important to Prevent Liver Cancer: Dr Izumi
April 13, 2009
- Daiichi Sankyo to Apply for DU-176b as Japan's First Oral Anti-Xa Agent
April 13, 2009
- Synergistic Effects Can Be Expected with Adoair
April 13, 2009
- Daiichi Sankyo Reshuffles R&D Structures to Quickly Develop Biologics
April 13, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…